Hebei Bohai Bioengineering Open Co., Ltd

1. Continue the NMPA registration work for different specifications of analytical reading systems and convenient terminal detection devices developed by Professor George Smoot. 2. Carry out the research and development of the "breast cancer specific multi target diagnosis and treatment scheme joint research and development cooperation demonstration" project as planned, and complete the annual task goal with quality and quantity guaranteed. Further promote the cooperative research with Duke University, and promote the implementation of the "in vivo and in vitro research project of multi-target individualized treatment of triple negative breast cancer" in the United States. Detecting the types and quantities of tumor targets in the serum of healthy, high-risk, or suspected tumor patients to determine the occurrence and development of tumors is a "sharp tool" for early detection of tumors. Early detection of the focus is earlier than the clinical routine means. Through early intervention, tumor cell proliferation and tumor development can be controlled, early detection and early treatment can reduce the incidence rate of tumors to the greatest extent. Secondly, through early screening, the screening data will be summarized and analyzed to provide a more reliable data basis for the statistical work of cancer incidence rate in China. By detecting specific tumor targets in the serum of confirmed patients and customizing their own sensitive cluster targets based on the detection results, a large number of immune cells with multi target recognition and killing ability are induced and cultivated. After transfusion, precise killing of the tumor is carried out, extending the patient's survival time and improving their survival, truly achieving more targeted and personalized immunotherapy. Additionally, it can be used in combination with targeted drugs such as PD-1 and is currently undergoing preclinical research.